Abstract


Levin VA¹, Tonge PJ¹, Gallo JM¹, Birtwistle MR¹, Dar AC¹, Iavarone A¹, Paddison PJ¹, Heffron TP¹, Elmquist WF¹, Lachowicz JE¹, Johnson TW¹, White FM¹, Sul J¹, Smith QR¹, Shen W¹, Sarkaria JN¹, Samala R¹, Wen PY¹, Berry DA¹, Petter RC¹.

Author information

Abstract

Following the first CNS Anticancer Drug Discovery and Development Conference, the speakers from the first 4 sessions and organizers of the conference created this White Paper hoping to stimulate more and better CNS anticancer drug discovery and development. The first part of the White Paper reviews, comments, and, in some cases, expands on the 4 session areas critical to new drug development: pharmacological challenges, recent drug approaches, drug targets and discovery, and clinical paths. Following this concise review of the science and clinical aspects of new CNS anticancer drug discovery and development, we discuss, under the rubric "Accelerating Drug Discovery and Development for Brain Tumors," further reasons why the pharmaceutical industry and academia have failed to develop new anticancer drugs for CNS malignancies and what it will take to change the current status quo and develop the drugs so desperately needed by our patients with malignant CNS tumors. While this White Paper is not a formal roadmap to that end, it should be an educational guide to clinicians and scientists to help move a stagnant field forward.

© The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

KEYWORDS: brain metastasis; chemotherapy; glioma; medulloblastoma; pharmacokinetics; pharmacology


LinkOut - more resources

PubMed Commons

0 comments

How to join PubMed Commons